# China Pharma Holdings, Inc. (CPHI)

> Source: Nexqual · https://nexqual.com/CPHI · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, China Pharma Holdings, Inc. (CPHI), nexqual.com/CPHI" · informational, not investment advice.

**Price:** USD 0.66 (-2.67% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0.68 · day 0.63–0.68 · 52w 0.38–19.19 · market cap $28.3M · ASE

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $3.9M, net income -$4.5M (-114.3% margin) (SEC filings).
- Total return with dividends: 1Y -63.7% vs S&P 500 +13.4%; 5Y -99.8% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $9.6M | $8.1M | $7.0M | $4.5M | $4.1M | $3.9M |
| Gross profit | $349K | -$494K | -$281K | -$2.0M | -$132K | — |
| Operating income | -$2.9M | -$3.5M | -$2.8M | -$4.6M | -$3.2M | -$4.4M |
| Net income | -$3.4M | -$4.0M | -$3.1M | -$4.7M | -$3.2M | -$4.5M |
| EPS (diluted) | -$37.00 | -$37.80 | -$9.10 | -$2.71 | -$0.74 | — |
| Free cash flow | -$688K | -$812K | -$711K | -$444K | $89K | — |
| Gross margin | 3.6% | -6.1% | -4.0% | -43.8% | -3.2% | — |
| Operating margin | -29.7% | -43.8% | -39.2% | -101.3% | -78.2% | -111.8% |
| Net margin | -35.3% | -49.0% | -43.9% | -104.6% | -76.9% | -114.3% |
| Revenue growth | -11.3% | -15.9% | -13.5% | -35.4% | -8.5% | — |
| Cash + short-term investments | $4.9M | $2.0M | $1.4M | $627K | $345K | — |
| Total debt | $5.3M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 7.2x · P/B 0.8x · Earnings yield -15.79%

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -63.7% | -99.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -63.9% | -71.1% |
| Volatility (annualized) | 300.1% | 91.7% |
| Max drawdown | -92.1% (Jul 2026→Oct 2026) | -99.8% (Oct 2021→Apr 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 40.7 -3.26% · BHC (Bausch Health Companies Inc.) USD 6.44 -0.77% · HCM (HUTCHMED (China) Limited) USD 14.36 +0.56% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.2 -4.80% · RGC (Regencell Bioscience Holdings L) USD 7.67 -21.81% · LQDA (Liquidia Corporation) USD 42.65 +7.46%

## More
Full page: https://nexqual.com/CPHI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2012-03-31) | — | — | — | $0 | — |
| Current fiscal year (ends 2011-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |